Clinical characteristics and prognostic factors of pulmonary and extrapulmonary cryptococcosis.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
20 Sep 2024
Historique:
received: 22 07 2024
accepted: 06 09 2024
medline: 21 9 2024
pubmed: 21 9 2024
entrez: 20 9 2024
Statut: epublish

Résumé

Cryptococcosis is progressively acknowledged among people, irrespective of the human with or without immunodeficiency virus (HIV). This change in epidemiology has been recorded in recent years, prompting closer examination and a broader understanding of the disease manifestations and risk factors. The data of cryptococcal infections in China during 11 years were retrospectively analyzed. According to the position of infection, the patients were categorized into the pulmonary infection group and extrapulmonary infection group. The composition of the two groups was compared, and the potential risk factors of disseminated infection were analyzed. Logistic regression was used to analyze the prognostic risk factors of the disease. A total of 165 patients were enrolled. 113 (68.5%) were male, and the age was 47.49 (18-82) years. 101 cases (61.2%) had a normal immune function and 64 cases (38.8%) had impaired immune function. 45 patients had extrapulmonary infection, involving the central nervous system, bone and joint, skin and bloodstream, and 120 patients had simple pulmonary infection. The mortality of the extrapulmonary infection group (48.9%) was significantly higher than that of the pulmonary infection group (0.8%). According to univariate logistic regression analysis, immune status (hazard ratio [HR], 4.476; 95% confidence interval [CI], 1.725-11.618; P = 0.002), infection position ([HR], 113.826; [CI], 14.607-886.967; P < 0.001), white blood cell count, ([HR],1.209;[CI], 1.054-1.386; P = 0.007), hemoglobin ([HR], 0.970; [CI], 0.955-0.986; P < 0.001), platelet count ([HR], 0.993; [CI], 0.987-0.999; P = 0.026), neutrophil percentage ([HR], 1.115; [CI], 1.065-1.168; P < 0.001), lymphocyte percentage ([HR], 0.875; [CI], 0.827-0.927; P < 0.001), neutrophil-to-lymphocyte Ratio (NLR) ([HR], 1.144; [CI], 1.072-1.221; P < 0.001), monocyte percentage ([HR], 0.752; [CI], 0.618-0.915; P = 0.004) were related to the prognosis. Multivariate logistic regression analysis showed that the infection position was remained related to the prognosis with statistical significance ([HR], 0.018; [CI], 0.001-0.384; P = 0.001). Extrapulmonary infection of Cryptococcosis is an important risk factor for prognosis. High levels of neutrophils and NLR, and low levels of lymphocytes and monocytes may lead to disseminated infection of Cryptococcosis. Further studies are needed to reduce the occurrence rate of extrapulmonary infection and mortality.

Sections du résumé

BACKGROUND BACKGROUND
Cryptococcosis is progressively acknowledged among people, irrespective of the human with or without immunodeficiency virus (HIV). This change in epidemiology has been recorded in recent years, prompting closer examination and a broader understanding of the disease manifestations and risk factors.
METHODS METHODS
The data of cryptococcal infections in China during 11 years were retrospectively analyzed. According to the position of infection, the patients were categorized into the pulmonary infection group and extrapulmonary infection group. The composition of the two groups was compared, and the potential risk factors of disseminated infection were analyzed. Logistic regression was used to analyze the prognostic risk factors of the disease.
RESULTS RESULTS
A total of 165 patients were enrolled. 113 (68.5%) were male, and the age was 47.49 (18-82) years. 101 cases (61.2%) had a normal immune function and 64 cases (38.8%) had impaired immune function. 45 patients had extrapulmonary infection, involving the central nervous system, bone and joint, skin and bloodstream, and 120 patients had simple pulmonary infection. The mortality of the extrapulmonary infection group (48.9%) was significantly higher than that of the pulmonary infection group (0.8%). According to univariate logistic regression analysis, immune status (hazard ratio [HR], 4.476; 95% confidence interval [CI], 1.725-11.618; P = 0.002), infection position ([HR], 113.826; [CI], 14.607-886.967; P < 0.001), white blood cell count, ([HR],1.209;[CI], 1.054-1.386; P = 0.007), hemoglobin ([HR], 0.970; [CI], 0.955-0.986; P < 0.001), platelet count ([HR], 0.993; [CI], 0.987-0.999; P = 0.026), neutrophil percentage ([HR], 1.115; [CI], 1.065-1.168; P < 0.001), lymphocyte percentage ([HR], 0.875; [CI], 0.827-0.927; P < 0.001), neutrophil-to-lymphocyte Ratio (NLR) ([HR], 1.144; [CI], 1.072-1.221; P < 0.001), monocyte percentage ([HR], 0.752; [CI], 0.618-0.915; P = 0.004) were related to the prognosis. Multivariate logistic regression analysis showed that the infection position was remained related to the prognosis with statistical significance ([HR], 0.018; [CI], 0.001-0.384; P = 0.001).
CONCLUSION CONCLUSIONS
Extrapulmonary infection of Cryptococcosis is an important risk factor for prognosis. High levels of neutrophils and NLR, and low levels of lymphocytes and monocytes may lead to disseminated infection of Cryptococcosis. Further studies are needed to reduce the occurrence rate of extrapulmonary infection and mortality.

Identifiants

pubmed: 39304813
doi: 10.1186/s12879-024-09895-9
pii: 10.1186/s12879-024-09895-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1018

Subventions

Organisme : Xiaowu Zhu famous doctor studio
ID : NO.CY2019002
Organisme : Xiaowu Zhu famous doctor studio
ID : NO.CY2019002
Organisme : Xiaowu Zhu famous doctor studio
ID : NO.CY2019002
Organisme : Xiaowu Zhu famous doctor studio
ID : NO.CY2019002
Organisme : Xiaowu Zhu famous doctor studio
ID : NO.CY2019002
Organisme : Xiaowu Zhu famous doctor studio
ID : NO.CY2019002
Organisme : Xiaowu Zhu famous doctor studio
ID : NO.CY2019002
Organisme : Xiaowu Zhu famous doctor studio
ID : NO.CY2019002
Organisme : Xiaowu Zhu famous doctor studio
ID : NO.CY2019002

Informations de copyright

© 2024. The Author(s).

Références

Mohamed SH, Nyazika TK, Ssebambulidde K, Lionakis MS, Meya DB, Drummond RA. Fungal CNS infections in Africa: the Neuroimmunology of Cryptococcal Meningitis. Front Immunol. 2022;13:804674.
pubmed: 35432326 pmcid: 9010970 doi: 10.3389/fimmu.2022.804674
Suwatanapongched T, Sangsatra W, Boonsarngsuk V, Watcharananan SP, Incharoen P. Clinical and radiologic manifestations of pulmonary cryptococcosis in immunocompetent patients and their outcomes after treatment. Diagn Interv Radiol. 2013;19(6):438–46.
pubmed: 23864332
Sun L, Chen H, Shao C, Song Y, Bai C. Pulmonary cryptococcosis with trachea wall invasion in an immunocompetent patient: a case report and literature review. Respiration. 2014;87(4):324–8.
pubmed: 24525662 doi: 10.1159/000357715
Gao LW, Jiao AX, Wu XR, Zhao SY, Ma Y, Liu G, et al. Clinical characteristics of disseminated cryptococcosis in previously healthy children in China. BMC Infect Dis. 2017;17(1):359.
pubmed: 28532447 pmcid: 5440943 doi: 10.1186/s12879-017-2450-5
Ngan NTT, Flower B, Day JN. Treatment of cryptococcal meningitis: how have we got Here and where are we. Going? Drugs. 2022;82(12):1237–49.
pubmed: 36112342 doi: 10.1007/s40265-022-01757-5
Zhu LP, Wu JQ, Xu B, Ou XT, Zhang QQ, Weng XH. Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997–2007. Med Mycol. 2010;48(4):570–9.
pubmed: 20392150 doi: 10.3109/13693780903437876
Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, Kwon-Chung KJ. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis. 2008;14(5):755–62.
pubmed: 18439357 pmcid: 2600263 doi: 10.3201/eid1405.071312
Li Z, Liu Y, Cao H, Huang S, Long M. Epidemiology and clinical characteristics of cryptococcal meningitis in China (1981–2013): a review of the literature. Med Mycology: Open Access. 2017;03(01).
Zhou L-H, Jiang Y-K, Li R-Y, Huang L-P, Yip C-W, Denning DW, et al. Risk-based Estimate of Human Fungal Disease Burden, China. Emerg Infect Dis. 2020;26(9):2137–47.
pubmed: 32818410 pmcid: 7454105 doi: 10.3201/eid2609.200016
Setianingrum F, Rautemaa-Richardson R, Denning D. Pulmonary cryptococcosis: a review of pathobiology and clinical aspects. Med Mycol. 2019;57(2):133–50.
pubmed: 30329097 doi: 10.1093/mmy/myy086
Donnelly J, Chen S, Kauffman C, Steinbach W, Baddley J, Verweij P, et al. Revision and update of the Consensus definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2020;71(6):1367–76.
doi: 10.1093/cid/ciz1008
Marr K, Sun Y, Spec A, Lu N, Panackal A, Bennett J, et al. A Multicenter, Longitudinal Cohort Study of Cryptococcosis in Human Immunodeficiency Virus-negative people in the United States. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2020;70(2):252–61.
doi: 10.1093/cid/ciz193
Decote-Ricardo D, LaRocque-de-Freitas IF, Rocha JDB, Nascimento DO, Nunes MP, Morrot A, et al. Immunomodulatory Role of Capsular Polysaccharides constituents of Cryptococcus neoformans. Front Med (Lausanne). 2019;6:129.
pubmed: 31275938 doi: 10.3389/fmed.2019.00129
Larocque-De-Freitas IF, Da Silva-Junior EB, Gemieski LP, Da Silva Dias Lima B, Diniz-Lima I, De Carvalho Vivarini A, et al. Inhibition of Microbicidal Activity of Canine macrophages DH82 Cell line by Capsular polysaccharides from Cryptococcus neoformans. J Fungi. 2024;10(5):339.
doi: 10.3390/jof10050339
Larocque-De-Freitas IF, Rocha JDB, Nunes MP, Oliveira PAV, Nascimento DDO, Freire-De-Lima L et al. Involvement of the capsular GalXM-induced IL-17 cytokine in the control of Cryptococcus neoformans infection. Sci Rep. 2018;8(1).
Villena SN, Pinheiro RO, Pinheiro CS, Nunes MP, Takiya CM, DosReis GA, et al. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand. Cell Microbiol. 2008;10(6):1274–85.
pubmed: 18284419 doi: 10.1111/j.1462-5822.2008.01125.x
Monari C, Paganelli F, Bistoni F, Kozel TR, Vecchiarelli A. Capsular polysaccharide induction of apoptosis by intrinsic and extrinsic mechanisms. Cell Microbiol. 2008;10(10):2129–37.
pubmed: 18647312 doi: 10.1111/j.1462-5822.2008.01196.x
Monari C, Pericolini E, Bistoni G, Casadevall A, Kozel TR, Vecchiarelli A. Cryptococcus neoformans capsular glucuronoxylomannan induces expression of fas ligand in macrophages. J Immunol. 2005;174(6):3461–8.
pubmed: 15749881 doi: 10.4049/jimmunol.174.6.3461
Lin C, Yang TY, Chan MC, Hsu KH, Huang YH, Tseng JS. Comprehensive Analysis and Risk Identification of Pulmonary Cryptococcosis in Non-HIV patients. J Fungi (Basel). 2021;7(8).
Tian Y, Wang J, Shen Y, Zhao J, Hu J, Zhu X, et al. Characteristics and prognostic risk factors of patients with sequence type 5 lineage-associated cryptococcosis in China. Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis. 2023;128:244–53.
Redlich S, Ribes S, Schütze S, Eiffert H, Nau R. Toll-like receptor stimulation increases phagocytosis of Cryptococcus neoformans by microglial cells. J Neuroinflammation. 2013;10:71.
pubmed: 23738865 pmcid: 3693974 doi: 10.1186/1742-2094-10-71
Wang DX, Zhang Q, Wen QT, Ding GX, Wang YG, Du FX, et al. Comparison of CT findings and histopathological characteristics of pulmonary cryptococcosis in immunocompetent and immunocompromised patients. Sci Rep. 2022;12(1):5712.
pubmed: 35383254 pmcid: 8983692 doi: 10.1038/s41598-022-09794-6
Hardison SE, Herrera G, Young ML, Hole CR, Wozniak KL, Wormley FL. Jr. Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation. J Immunol. 2012;189(8):4060–8.
pubmed: 22984078 pmcid: 3466339 doi: 10.4049/jimmunol.1103455
De Leon-Rodriguez CM, Rossi DCP, Fu MS, Dragotakes Q, Coelho C, Guerrero Ros I, et al. The outcome of the Cryptococcus neoformans-Macrophage Interaction depends on phagolysosomal membrane Integrity. J Immunol. 2018;201(2):583–603.
pubmed: 29858266 doi: 10.4049/jimmunol.1700958
Alvarez M, Casadevall A. Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol. 2007;8(1):16.
pubmed: 17705844 pmcid: 1988836 doi: 10.1186/1471-2172-8-16
Chrisman CJ, Albuquerque P, Guimaraes AJ, Nieves E, Casadevall A. Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages. PLoS Pathog. 2011;7(5):e1002047.
pubmed: 21637814 pmcid: 3102711 doi: 10.1371/journal.ppat.1002047
Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci U S A. 2000;97(16):8841–8.
pubmed: 10922044 pmcid: 34021 doi: 10.1073/pnas.97.16.8841
Leopold Wager CM, Hole CR, Wozniak KL, Olszewski MA, Wormley FL. Jr. STAT1 signaling is essential for protection against Cryptococcus neoformans infection in mice. J Immunol. 2014;193(8):4060–71.
pubmed: 25200956 doi: 10.4049/jimmunol.1400318
Leopold Wager CM, Hole CR, Wozniak KL, Olszewski MA, Mueller M, Wormley FL. Jr. STAT1 signaling within macrophages is required for antifungal activity against Cryptococcus neoformans. Infect Immun. 2015;83(12):4513–27.
pubmed: 26351277 pmcid: 4645398 doi: 10.1128/IAI.00935-15
Campuzano A, Castro-Lopez N, Martinez AJ, Olszewski MA, Ganguly A, Leopold Wager C et al. CARD9 is required for classical macrophage activation and the induction of protective immunity against Pulmonary Cryptococcosis. mBio. 2020;11(1).
Viola GM, Malek AE, Rosen LB, DiNardo AR, Nishiguchi T, Okhuysen PC, et al. Disseminated cryptococcosis and anti-granulocyte-macrophage colony-stimulating factor autoantibodies: an underappreciated association. Mycoses. 2021;64(6):576–82.
pubmed: 33476401 doi: 10.1111/myc.13247
Han Q, Wen X, Wang L, Han X, Shen Y, Cao J, et al. Role of hematological parameters in the diagnosis of influenza virus infection in patients with respiratory tract infection symptoms. J Clin Lab Anal. 2020;34(5):e23191.
pubmed: 31901184 pmcid: 7246361 doi: 10.1002/jcla.23191
Liu S, Wang X, She F, Zhang W, Liu H, Zhao X. Effects of Neutrophil-to-lymphocyte ratio combined with Interleukin-6 in Predicting 28-Day mortality in patients with Sepsis. Front Immunol. 2021;12:639735.
pubmed: 33796105 pmcid: 8007868 doi: 10.3389/fimmu.2021.639735
Zhang K, Li H, Zhang L, Liao W, Cai L, Li X, et al. The change in the Neutrophil/Lymphocyte ratio predicts the prognosis of patients with cryptococcal meningitis. Mycopathologia. 2021;186(6):857–62.
pubmed: 34467475 doi: 10.1007/s11046-021-00553-1
Wang Y, Wei H, Shen L, Su X, Liu J, Xu X, et al. Immunological predictors of Post Infectious Inflammatory Response Syndrome in HIV-Negative immunocompetent cryptococcal meningitis. Front Immunol. 2022;13:895456.
pubmed: 35686135 pmcid: 9171325 doi: 10.3389/fimmu.2022.895456
Shi J, Chen J, Hu L, Ma AHY, Hu H, Wang C, et al. Retrospective analysis of pulmonary cryptococcosis and extrapulmonary cryptococcosis in a Chinese tertiary hospital. BMC Pulm Med. 2023;23(1):277.
pubmed: 37501136 pmcid: 10375642 doi: 10.1186/s12890-023-02578-2
Mednick AJ, Feldmesser M, Rivera J, Casadevall A. Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur J Immunol. 2003;33(6):1744–53.
pubmed: 12778493 doi: 10.1002/eji.200323626
Wozniak KL, Kolls JK, Wormley FL. Depletion of neutrophils in a protective model of pulmonary cryptococcosis results in increased IL-17A production by gamma/delta T cells. BMC Immunol. 2012;13(1):65.
pubmed: 23216912 pmcid: 3538069 doi: 10.1186/1471-2172-13-65
Hazeldine J, Lord J. Neutrophils and COVID-19: active participants and rational therapeutic targets. Front Immunol. 2021;12:680134.
pubmed: 34149717 pmcid: 8206563 doi: 10.3389/fimmu.2021.680134
Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19: immunopathogenesis and immunotherapeutics. Signal Transduct Target Therapy. 2020;5(1):128.
doi: 10.1038/s41392-020-00243-2
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Med. 2020;8(4):420–22.
doi: 10.1016/S2213-2600(20)30076-X
Zhao H, Zhou M, Zheng Q, Zhu M, Yang Z, Hu C, et al. Clinical features and outcomes of Cryptococcemia patients with and without HIV infection. Mycoses. 2021;64(6):656–67.
pubmed: 33609302 doi: 10.1111/myc.13261
Zheng H, Chen Q, Xie Z, Wang D, Li M, Zhang X, et al. A retrospective research of HIV-negative cryptococcal meningoencephalitis patients with acute/subacute onset. Eur J Clin Microbiol Infect Dis. 2016;35(2):299–303.
pubmed: 26792138 doi: 10.1007/s10096-015-2545-0
Liu S, Chen W, Cheng F, Ye X, Pan N, Lu H. Clinical characteristics and prognostic factors of 60 patients with acquired immune deficiency syndrome combined with Cryptococcus neoformans. BMC Infect Dis. 2023;23(1):204.
pubmed: 37024795 pmcid: 10080839 doi: 10.1186/s12879-023-08137-8
Chang Y, Stins M, McCaffery M, Miller G, Pare D, Dam T, et al. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun. 2004;72(9):4985–95.
pubmed: 15321990 pmcid: 517459 doi: 10.1128/IAI.72.9.4985-4995.2004
Stie J, Fox D. Blood-brain barrier invasion by Cryptococcus neoformans is enhanced by functional interactions with plasmin. Microbiology. 2012;158:240–58.
pubmed: 21998162 pmcid: 3352358 doi: 10.1099/mic.0.051524-0
Liu T, Perlin D, Xue C. Molecular mechanisms of cryptococcal meningitis. Virulence. 2012;3(2):173–81.
pubmed: 22460646 pmcid: 3396696 doi: 10.4161/viru.18685
Sabiiti W, May R. Capsule independent uptake of the fungal pathogen Cryptococcus neoformans into brain microvascular endothelial cells. PLoS ONE. 2012;7(4):e35455.
pubmed: 22530025 pmcid: 3328471 doi: 10.1371/journal.pone.0035455
Jong A, Wu C, Gonzales-Gomez I, Kwon-Chung K, Chang Y, Tseng H, et al. Hyaluronic acid receptor CD44 deficiency is associated with decreased Cryptococcus neoformans brain infection. J Biol Chem. 2012;287(19):15298–306.
pubmed: 22418440 pmcid: 3346080 doi: 10.1074/jbc.M112.353375
Jong A, Wu C-H, Shackleford GM, Kwon-Chung KJ, Chang YC, Chen H-M, et al. Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells. Cell Microbiol. 2008;10(6):1313–26.
pubmed: 18248627 doi: 10.1111/j.1462-5822.2008.01128.x
Huang SH, Long M, Wu CH, Kwon-Chung KJ, Chang YC, Chi F, et al. Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells is mediated through the lipid rafts-endocytic pathway via the dual specificity tyrosine phosphorylation-regulated kinase 3 (DYRK3). J Biol Chem. 2011;286(40):34761–9.
pubmed: 21693704 pmcid: 3186382 doi: 10.1074/jbc.M111.219378
Long M, Huang SH, Wu CH, Shackleford GM, Jong A. Lipid raft/caveolae signaling is required for Cryptococcus neoformans invasion into human brain microvascular endothelial cells. J Biomed Sci. 2012;19(1):19.
pubmed: 22316086 pmcid: 3308189 doi: 10.1186/1423-0127-19-19
Jong A, Wu CH, Chen HM, Luo F, Kwon-Chung KJ, Chang YC, et al. Identification and characterization of CPS1 as a hyaluronic acid synthase contributing to the pathogenesis of Cryptococcus neoformans infection. Eukaryot Cell. 2007;6(8):1486–96.
pubmed: 17545316 pmcid: 1951127 doi: 10.1128/EC.00120-07
Chang YC, Stins MF, McCaffery MJ, Miller GF, Pare DR, Dam T, et al. Cryptococcal yeast cells invade the Central Nervous System via Transcellular Penetration of the blood-brain barrier. Infect Immun. 2004;72(9):4985–95.
pubmed: 15321990 pmcid: 517459 doi: 10.1128/IAI.72.9.4985-4995.2004
Kim KS. Mechanisms of microbial traversal of the blood–brain barrier. Nat Rev Microbiol. 2008;6(8):625–34.
pubmed: 18604221 pmcid: 5206914 doi: 10.1038/nrmicro1952
Maruvada R, Zhu L, Pearce D, Zheng Y, Perfect J, Kwon-Chung KJ, et al. Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier. Cell Microbiol. 2012;14(10):1544–53.
pubmed: 22646320 pmcid: 3443264 doi: 10.1111/j.1462-5822.2012.01819.x
He X, Shi X, Puthiyakunnon S, Zhang L, Zeng Q, Li Y, et al. CD44-mediated monocyte transmigration across Cryptococcus neoformans-infected brain microvascular endothelial cells is enhanced by HIV-1 gp41-I90 ectodomain. J Biomed Sci. 2016;23:28.
pubmed: 26897523 pmcid: 4761181 doi: 10.1186/s12929-016-0247-2
Deboux C, Ladraa S, Cazaubon S, Ghribi-Mallah S, Weiss N, Chaverot N, et al. Overexpression of CD44 in neural precursor cells improves trans-endothelial migration and facilitates their invasion of perivascular tissues in vivo. PLoS ONE. 2013;8(2):e57430.
pubmed: 23468987 pmcid: 3585392 doi: 10.1371/journal.pone.0057430
Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, et al. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer. 2012;12:458.
pubmed: 23039365 pmcid: 3517483 doi: 10.1186/1471-2407-12-458
Hou C, Ishi Y, Motegi H, Okamoto M, Ou Y, Chen J, et al. Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas. J Neurooncol. 2019;145(2):201–10.
pubmed: 31506754 doi: 10.1007/s11060-019-03288-8
Liu Y, Wu T, Lu D, Zhen J, Zhang L. CD44 overexpression related to lymph node metastasis and poor prognosis of pancreatic cancer. Int J Biol Markers. 2018;33(3):308–13.
pubmed: 29683068 doi: 10.1177/1724600817746951
Grisar J, Munk M, Steiner CW, Amoyo-Minar L, Tohidast-Akrad M, Zenz P, et al. Expression patterns of CD44 and CD44 splice variants in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(1):64–72.
pubmed: 22261341

Auteurs

Ziwei Tao (Z)

Department of Infectious Disease, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230000, China.

Qinqin Pu (Q)

Department of Infectious Disease, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.

Yongli Shen (Y)

Department of Infectious Disease, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.

Sicheng Zhang (S)

Department of Acute and Critical Care Medicine, Hefei First People's Hospital, Hefei, 230001, China.

Chuanyou Wang (C)

Department of Infectious Disease, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230000, China.

Zhe Hu (Z)

Department of Infectious Disease, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230000, China.

Yi Jin (Y)

Department of Gastroenterology, Jiangsu Provincial Rongjun Hospital, Wuxi, 214000, China.

Xiaowu Zhu (X)

Department of Infectious Disease, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230000, China. 13365517957@189.cn.

Yali Weng (Y)

Department of Infectious Disease, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. wengyali@njmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH